The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 04, 2025

Filed:

Feb. 20, 2019
Applicant:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Inventors:

Gregory P. Chang, Medford, MA (US);

Ann F. Cheung, Lincoln, MA (US);

Asya Grinberg, Lexington, MA (US);

Dhruv Kam Sethi, Belmont, MA (US);

William Haney, Wayland, MA (US);

Bianka Prinz, Lebanon, NH (US);

Bradley M. Lunde, Lebanon, NH (US);

Ronnie Wei, Weston, MA (US);

Daniel Fallon, Winchester, MA (US);

Steven O'Neil, Wayland, MA (US);

Assignee:

Dragonfly Therapeutics, Inc., Waltham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/283 (2013.01); C07K 2317/31 (2013.01); C07K 2317/522 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01);
Abstract

Multi-specific binding proteins that bind to and kill human cancer cells expressing CD33 (Siglec-3) are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of CD33 expressing cancer. The invention relates to multi-specific binding proteins that bind to human cancer cells expressing CD33 and exhibit high potency and maximum lysis of target cells compared to anti-CD33 monoclonal antibodies. The multi-specific binding proteins comprise a CD33-binding domain, an NKG2D-binding domain and a CD16-binding domain.


Find Patent Forward Citations

Loading…